Episode #243. It’s time to face the facts on saturated fat. Dr Gil Carvalho returns to examine a bold new study on this controversial topic, breaking down whether you need to reconsider your food choices in the wake of this study’s release.

We discuss:

Intro (00:00)
Saturated fat misunderstandings: Is saturated fat bad? (17:20)
Principle 1: Dose matters? — How much saturated fat is too much? (22:07)
Is no saturated fat the goal? (30:12)
Principle 2: Replacement nutrient matters (31:54)
Principle 3: Source matters (45:53)
Mechanisms: Saturated fat and heart disease (50:48)
Saturated fats and genetics (55:47)
Target ApoB level (59:40)
Importance of lifetime exposure (1:03:02)
Statins and heart disease risk: Are statins bad for you? (1:08:53)
Mendelian randomization studies (1:10:52)
The totality of evidence (1:15:59)
Saturated fats and total mortality (1:17:46)
Saturated fat and liver health (1:19:51)
Gaps in the research (1:20:43)
Common arguments against lowering saturated fat (1:23:52)
Outro (1:38:36)

To explore more of Dr Gil Carvalho’s work, you can find him on YouTube. You can also connect with him on Twitter and Facebook, and listen to our previous conversation in Episode #207.

Discover more insights and supporting studies in the full show notes.

Enjoy, friends.

Simon

Want to support the show?

The best way to support the show is to use the products and services offered by our sponsors. To check them out, and enjoy great savings, visit theproof.com/friends. You can also show your support by leaving a review on the Apple Podcast app and/or sharing your favourite episodes with your friends and family.

Simon Hill, MSc, BSc (Hons)

Creator of theproof.com and host of The Proof with Simon Hill

Author of The Proof is in the Plants

Watch the episodes on YouTube or listen on Apple/Spotify

Connect with me on Instagram, Twitter, and Facebook

Nourish your gut with my Plant-Based Ferments Guide

Download my complimentary

two-week meal plan and high protein Plant Performance recipe book

Pills #10 WIZS3: O turnaround que o mercado ainda não acredita